Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Bio Path Holdings Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
BPTH
Nasdaq
8731
https://www.biopathholdings.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Bio Path Holdings Inc
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Apr 18th, 2024 5:57 pm
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
- Apr 18th, 2024 11:00 am
Bio-Path Holdings Expands Global Patent Portfolio
- Apr 15th, 2024 11:00 am
Bio-Path Holdings Provides 2024 Clinical and Operational Update
- Apr 2nd, 2024 11:00 am
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23
- Mar 27th, 2024 8:43 pm
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q4 2023 Earnings Call Transcript
- Mar 10th, 2024 12:17 pm
Q4 2023 Bio Path Holdings Inc Earnings Call
- Mar 9th, 2024 3:45 am
Bio-Path Holdings Reports Full Year 2023 Financial Results
- Mar 8th, 2024 12:00 pm
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
- Mar 1st, 2024 12:00 pm
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
- Feb 21st, 2024 12:00 pm
When Can We Expect A Profit From Bio-Path Holdings, Inc. (NASDAQ:BPTH)?
- Feb 17th, 2024 2:28 pm
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients
- Jan 10th, 2024 12:00 pm
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
- Dec 14th, 2023 12:00 pm
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q3 2023 Earnings Call Transcript
- Nov 20th, 2023 5:54 pm
Bio-Path Holdings Reports Third Quarter 2023 Financial Results
- Nov 15th, 2023 12:00 pm
Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023
- Nov 8th, 2023 12:00 pm
Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia
- Oct 24th, 2023 11:00 am
Bio-Path Holdings, Inc.'s (NASDAQ:BPTH) Profit Outlook
- Sep 10th, 2023 1:59 pm
Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference
- Sep 8th, 2023 8:01 pm
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 23
- Aug 30th, 2023 9:11 pm
Scroll